Cellular senescence in cancer treatment: friend or foe?

@article{Kahlem2004CellularSI,
  title={Cellular senescence in cancer treatment: friend or foe?},
  author={Pascal Kahlem and Bernd Doerken and Clemens A. Schmitt},
  journal={The Journal of clinical investigation},
  year={2004},
  volume={113 2},
  pages={169-74}
}
Damage to DNA, the prime target of anticancer therapy, triggers programmed cellular responses. In addition to apoptosis, therapy-mediated premature senescence has been identified as another drug-responsive program that impacts the outcome of cancer therapy. Here, we discuss whether induction of senescence is a beneficial or, rather, a detrimental consequence of the therapeutic intervention. 

From This Paper

Figures, tables, and topics from this paper.
50 Citations
48 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 48 references

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

  • J. C. Chang
  • Lancet .
  • 2003

Similar Papers

Loading similar papers…